Shots:

• The pediatric expansion of the P-III (PREVENT-19) trial evaluates NVX-CoV2373 vs PBO in a ratio (2:1) in 2247 adolescents aged 12 through 17yrs. with COVID-19 at 73 sites in the US
• The results showed that patients achieved primary effectiveness EPs with neutralizing Ab responses non-inferior to those observed in young-adult, 82% clinical efficacy against Delta variant, immune responses were 2 to 3 fold higher in adolescents than adults, was well-tolerated & no safety signals were observed
• The company is planning to submit the regulatory filings in Q1’22 & will initiate an additional study globally for younger patients in Q2’22. The vaccine is currently under multiple regulatory agencies’ review

Ref: Businesswire | Image: Novavax